missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Tocris Bioscience™ DD 03-171

Click to view available options
Quantity:
5 mg
Unit Size:
5mg
Description
DD 03-171 is a potent and selective BTK Degrader (PROTAC™) (IC50 = 5.1 nM); degrades BTK in a proteasome- and CRBN-dependent manner. Suppresses BTK signaling and proliferation in mantle cell lymphoma (MCL) cells by degrading BTK, IKFZ1, and IKFZ3 (3 validated targets in B-cell malignancies). Also degrades Ibrutinib (Cat. No. 6813) -resistant C481S-BTK mutant cancer cells. Exhibits no binding against a panel of 468 kinases at 1 μM. Reduces tumor burden and extends survival in lymphoma patient-derived xenograft models. PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Specifications
Specifications
| Chemical Name or Material | 4-(1,1-Dimethylethyl)-N-[3-[6-[[4-[[4-[6-[[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1 H-isoindol-4-yl]amino]acetyl]amino]hexyl]-1-piperazinyl]carbonyl]phenyl]amino]-4,5-dihydro-4-methyl-5-oxo-2-pyrazinyl]-2-methylphenyl]benzamide |
| CAS | 2366132-45-6 |
| Quantity | 5 mg |
| Target | Active Degraders |
| Molecular Formula | C55H62N10O8 |
| Purity | 0.98 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction